{
    "info": {
        "nct_id": "NCT06084936",
        "official_title": "A Phase III, Open-Label, Multicenter Randomized Study Evaluating Glofitamab as a Single Agent Versus Investigator's Choice in Patients With Relapsed/Refractory Mantle Cell Lymphoma",
        "inclusion_criteria": "* Life expectancy at least 12 weeks\n* Histologically-confirmed MCL, with documentation of either overexpression of cyclin D1 or the presence of t(11:14)\n* Relapsed (disease progression after the last treatment regimen) or refractory (failure to achieve a partial or complete response from the last treatment regimen) disease\n* At least 1 line of prior systemic therapy including a BTK inhibitor and additional systemic therapy option\n* Confirmed availability of tumor tissue, unless deemed unsafe per investigator assessment\n* At least one bi-dimensionally measurable (defined as at least 1.5 cm) nodal lesion, or one bi-dimensionally measurable (at least 1 cm) extranodal lesion, as measured on CT scan\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2\n* Negative HIV test at screening\n* Adequate hematological function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 3 months after the final dose of tocilizumab, 2 months after the final dose of glofitamab, whichever is longer\n* Leukemic, non-nodal MCL\n* History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies (or recombinant antibody-related fusion proteins) or known sensitivity or allergy to murine products\n* Contraindication to obinutuzumab or rituximab, and either bendamustine or lenalidomide\n* Prior treatment with glofitamab or other bispecific antibodies targeting both CD20 and CD3\n* Prior treatment with CAR-T cell therapy\n* Treatment with systemic therapy or BTK inhibitors, or any investigational agent for the purposes of treating cancer within 2 weeks or 5 half-lives (whichever is shorter) prior to first study treatment\n* Primary or secondary CNS lymphoma at the time of recruitment or history of CNS lymphoma\n* Current or history of CNS disease, such as stroke, epilepisy, CNS vasculitis, or neurodegenerative disease\n* History of other malignancy that could affect compliance with the protocol or interpretation of results\n* Significant or extensive cardiovascular disease\n* Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection at study enrollment or any major episode of infection within 4 weeks prior to the first study treatment\n* Suspected or latent tuberculosis\n* Positive test for hepatitis B virus (HBV) or hepatitis C virus (HCV)\n* Known or suspected chronic active Epstein-Barr viral infection (EBV)\n* Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)\n* Known history of progressive multifocal leukoencephalopathy (PML)\n* Adverse events from prior anti-cancer therapy that have not resolved to Grade 1 or better\n* Administration of a live, attenuated vaccine within 4 weeks before first study treatment administration or anticipation that such a live, attenuated vaccine will be required during the study\n* Prior solid organ transplantation or allogenic stem cell transplant\n* Eligibility for stem cell transplantation (SCT)\n* Active autoimmune disease requiring treatment\n* Prior treatment with systemic immunosuppressive medications within 2 weeks or five half-lives (whichever is shorter) prior to the first dose of study treatment\n* Corticosteroid therapy within 2 weeks prior to first dose of study treatment\n* Recent major surgery (within 4 weeks before the first study treatment) other than for diagnosis\n* Clinically significant history of cirrhotic liver disease",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Life expectancy at least 12 weeks",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy at least 12 weeks",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically-confirmed MCL, with documentation of either overexpression of cyclin D1 or the presence of t(11:14)",
            "criterions": [
                {
                    "exact_snippets": "Histologically-confirmed MCL",
                    "criterion": "mantle cell lymphoma (MCL)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis confirmation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "overexpression of cyclin D1",
                    "criterion": "cyclin D1 expression",
                    "requirements": [
                        {
                            "requirement_type": "overexpression",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "presence of t(11:14)",
                    "criterion": "t(11:14) translocation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Confirmed availability of tumor tissue, unless deemed unsafe per investigator assessment",
            "criterions": [
                {
                    "exact_snippets": "Confirmed availability of tumor tissue",
                    "criterion": "tumor tissue",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unless deemed unsafe per investigator assessment",
                    "criterion": "tumor tissue collection safety",
                    "requirements": [
                        {
                            "requirement_type": "investigator assessment of safety",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Negative HIV test at screening",
            "criterions": [
                {
                    "exact_snippets": "Negative HIV test at screening",
                    "criterion": "HIV test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate hematological function",
            "criterions": [
                {
                    "exact_snippets": "Adequate hematological function",
                    "criterion": "hematological function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": [
                                "0",
                                "1",
                                "2"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Relapsed (disease progression after the last treatment regimen) or refractory (failure to achieve a partial or complete response from the last treatment regimen) disease",
            "criterions": [
                {
                    "exact_snippets": "Relapsed (disease progression after the last treatment regimen)",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "relapsed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "refractory (failure to achieve a partial or complete response from the last treatment regimen)",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "refractory",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* At least 1 line of prior systemic therapy including a BTK inhibitor and additional systemic therapy option",
            "criterions": [
                {
                    "exact_snippets": "At least 1 line of prior systemic therapy",
                    "criterion": "prior systemic therapy",
                    "requirements": [
                        {
                            "requirement_type": "number of lines",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lines"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "including a BTK inhibitor",
                    "criterion": "prior BTK inhibitor therapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "additional systemic therapy option",
                    "criterion": "additional systemic therapy option",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* At least one bi-dimensionally measurable (defined as at least 1.5 cm) nodal lesion, or one bi-dimensionally measurable (at least 1 cm) extranodal lesion, as measured on CT scan",
            "criterions": [
                {
                    "exact_snippets": "At least one bi-dimensionally measurable (defined as at least 1.5 cm) nodal lesion",
                    "criterion": "nodal lesion",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        },
                        {
                            "requirement_type": "measurability",
                            "expected_value": "bi-dimensionally measurable"
                        },
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "cm"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "one bi-dimensionally measurable (at least 1 cm) extranodal lesion",
                    "criterion": "extranodal lesion",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        },
                        {
                            "requirement_type": "measurability",
                            "expected_value": "bi-dimensionally measurable"
                        },
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "cm"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Suspected or latent tuberculosis",
            "criterions": [
                {
                    "exact_snippets": "Suspected or latent tuberculosis",
                    "criterion": "tuberculosis",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "suspected",
                                "latent"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with CAR-T cell therapy",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with CAR-T cell therapy",
                    "criterion": "CAR-T cell therapy",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior solid organ transplantation or allogenic stem cell transplant",
            "criterions": [
                {
                    "exact_snippets": "Prior solid organ transplantation",
                    "criterion": "solid organ transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "allogenic stem cell transplant",
                    "criterion": "allogenic stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eligibility for stem cell transplantation (SCT)",
            "criterions": [
                {
                    "exact_snippets": "Eligibility for stem cell transplantation (SCT)",
                    "criterion": "stem cell transplantation eligibility",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Leukemic, non-nodal MCL",
            "criterions": [
                {
                    "exact_snippets": "Leukemic",
                    "criterion": "leukemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "non-nodal MCL",
                    "criterion": "mantle cell lymphoma (MCL)",
                    "requirements": [
                        {
                            "requirement_type": "nodal involvement",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)",
            "criterions": [
                {
                    "exact_snippets": "Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)",
                    "criterion": "hemophagocytic lymphohistiocytosis (HLH)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "certainty",
                            "expected_value": [
                                "known",
                                "suspected"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current or history of CNS disease, such as stroke, epilepisy, CNS vasculitis, or neurodegenerative disease",
            "criterions": [
                {
                    "exact_snippets": "Current or history of CNS disease",
                    "criterion": "CNS disease",
                    "requirements": [
                        {
                            "requirement_type": "presence or history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "stroke",
                    "criterion": "stroke",
                    "requirements": [
                        {
                            "requirement_type": "presence or history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "epilepisy",
                    "criterion": "epilepsy",
                    "requirements": [
                        {
                            "requirement_type": "presence or history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "CNS vasculitis",
                    "criterion": "CNS vasculitis",
                    "requirements": [
                        {
                            "requirement_type": "presence or history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "neurodegenerative disease",
                    "criterion": "neurodegenerative disease",
                    "requirements": [
                        {
                            "requirement_type": "presence or history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies (or recombinant antibody-related fusion proteins) or known sensitivity or allergy to murine products",
            "criterions": [
                {
                    "exact_snippets": "History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies (or recombinant antibody-related fusion proteins)",
                    "criterion": "allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or recombinant antibody-related fusion proteins",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "known sensitivity or allergy to murine products",
                    "criterion": "sensitivity or allergy to murine products",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active autoimmune disease requiring treatment",
            "criterions": [
                {
                    "exact_snippets": "Active autoimmune disease requiring treatment",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of other malignancy that could affect compliance with the protocol or interpretation of results",
            "criterions": [
                {
                    "exact_snippets": "History of other malignancy",
                    "criterion": "history of other malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "could affect compliance with the protocol",
                    "criterion": "potential to affect compliance with the protocol",
                    "requirements": [
                        {
                            "requirement_type": "potential impact",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "could affect ... interpretation of results",
                    "criterion": "potential to affect interpretation of results",
                    "requirements": [
                        {
                            "requirement_type": "potential impact",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinically significant history of cirrhotic liver disease",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant history of cirrhotic liver disease",
                    "criterion": "cirrhotic liver disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known or suspected chronic active Epstein-Barr viral infection (EBV)",
            "criterions": [
                {
                    "exact_snippets": "Known or suspected chronic active Epstein-Barr viral infection (EBV)",
                    "criterion": "chronic active Epstein-Barr viral infection (EBV)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "known",
                                "suspected"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Corticosteroid therapy within 2 weeks prior to first dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Corticosteroid therapy within 2 weeks prior to first dose of study treatment",
                    "criterion": "corticosteroid therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last use",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known history of progressive multifocal leukoencephalopathy (PML)",
            "criterions": [
                {
                    "exact_snippets": "Known history of progressive multifocal leukoencephalopathy (PML)",
                    "criterion": "progressive multifocal leukoencephalopathy (PML)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adverse events from prior anti-cancer therapy that have not resolved to Grade 1 or better",
            "criterions": [
                {
                    "exact_snippets": "Adverse events from prior anti-cancer therapy that have not resolved to Grade 1 or better",
                    "criterion": "adverse events from prior anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "CTCAE grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with glofitamab or other bispecific antibodies targeting both CD20 and CD3",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with glofitamab",
                    "criterion": "prior treatment with glofitamab",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "other bispecific antibodies targeting both CD20 and CD3",
                    "criterion": "prior treatment with bispecific antibodies targeting both CD20 and CD3",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with systemic immunosuppressive medications within 2 weeks or five half-lives (whichever is shorter) prior to the first dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with systemic immunosuppressive medications within 2 weeks or five half-lives (whichever is shorter) prior to the first dose of study treatment",
                    "criterion": "prior treatment with systemic immunosuppressive medications",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Positive test for hepatitis B virus (HBV) or hepatitis C virus (HCV)",
            "criterions": [
                {
                    "exact_snippets": "Positive test for hepatitis B virus (HBV)",
                    "criterion": "hepatitis B virus (HBV) infection",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "Positive test for ... hepatitis C virus (HCV)",
                    "criterion": "hepatitis C virus (HCV) infection",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Recent major surgery (within 4 weeks before the first study treatment) other than for diagnosis",
            "criterions": [
                {
                    "exact_snippets": "Recent major surgery (within 4 weeks before the first study treatment)",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "purpose",
                            "expected_value": {
                                "operator": "!=",
                                "value": 1,
                                "unit": "diagnosis"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 3 months after the final dose of tocilizumab, 2 months after the final dose of glofitamab, whichever is longer",
            "criterions": [
                {
                    "exact_snippets": "Pregnancy",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "intention of becoming pregnant during the study or within 3 months after the final dose of tocilizumab, 2 months after the final dose of glofitamab, whichever is longer",
                    "criterion": "intention to become pregnant",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window after final dose",
                            "expected_value": "during the study or within 3 months after the final dose of tocilizumab, 2 months after the final dose of glofitamab, whichever is longer"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection at study enrollment or any major episode of infection within 4 weeks prior to the first study treatment",
            "criterions": [
                {
                    "exact_snippets": "Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection at study enrollment",
                    "criterion": "active infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "any major episode of infection within 4 weeks prior to the first study treatment",
                    "criterion": "major episode of infection",
                    "requirements": [
                        {
                            "requirement_type": "time since last episode",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Contraindication to obinutuzumab or rituximab, and either bendamustine or lenalidomide",
            "criterions": [
                {
                    "exact_snippets": "Contraindication to obinutuzumab",
                    "criterion": "obinutuzumab",
                    "requirements": [
                        {
                            "requirement_type": "contraindication",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Contraindication to ... rituximab",
                    "criterion": "rituximab",
                    "requirements": [
                        {
                            "requirement_type": "contraindication",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Contraindication to ... either bendamustine or lenalidomide",
                    "criterion": "bendamustine",
                    "requirements": [
                        {
                            "requirement_type": "contraindication",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Contraindication to ... either bendamustine or lenalidomide",
                    "criterion": "lenalidomide",
                    "requirements": [
                        {
                            "requirement_type": "contraindication",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with systemic therapy or BTK inhibitors, or any investigational agent for the purposes of treating cancer within 2 weeks or 5 half-lives (whichever is shorter) prior to first study treatment",
            "criterions": [
                {
                    "exact_snippets": "Treatment with systemic therapy ... within 2 weeks or 5 half-lives (whichever is shorter) prior to first study treatment",
                    "criterion": "systemic therapy",
                    "requirements": [
                        {
                            "requirement_type": "recency of treatment",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Treatment with ... BTK inhibitors ... within 2 weeks or 5 half-lives (whichever is shorter) prior to first study treatment",
                    "criterion": "BTK inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "recency of treatment",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Treatment with ... any investigational agent for the purposes of treating cancer within 2 weeks or 5 half-lives (whichever is shorter) prior to first study treatment",
                    "criterion": "investigational agent for the purposes of treating cancer",
                    "requirements": [
                        {
                            "requirement_type": "recency of treatment",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Administration of a live, attenuated vaccine within 4 weeks before first study treatment administration or anticipation that such a live, attenuated vaccine will be required during the study",
            "criterions": [
                {
                    "exact_snippets": "Administration of a live, attenuated vaccine within 4 weeks before first study treatment administration",
                    "criterion": "live, attenuated vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration before first study treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "administration",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "anticipation that such a live, attenuated vaccine will be required during the study",
                    "criterion": "anticipated need for live, attenuated vaccine",
                    "requirements": [
                        {
                            "requirement_type": "anticipated requirement during study",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* Primary or secondary CNS lymphoma at the time of recruitment or history of CNS lymphoma",
            "criterions": []
        },
        {
            "line": "* Significant or extensive cardiovascular disease",
            "criterions": []
        }
    ],
    "failed_miscellaneous": []
}